Global Human Combination Vaccines Market 2017-2021

ヒト混合ワクチンの世界市場2017-2021

◆タイトル:Global Human Combination Vaccines Market 2017-2021
◆商品コード:IRTNTR12763
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年6月14日
◆ページ数:86
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、ヒト混合ワクチンの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、ヒト混合ワクチンの世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Human Combination VaccinesA vaccine is made up of inactive, partially killed or dead viruses, to stimulate the immune system against the pathogenic virus and produce antibodies against it. Vaccines are injected or orally administered. Animal vaccines provide immunity to the animal body against pathogens. They are composed of attenuated or dead virus strains and can be administered via the intramuscular, intradermal, or oral route. Similarly, human vaccines are composed of inactivated or live attenuated virus particles and provide immunity to the human body against different pathogens and can be administered via the intramuscular, intradermal, oral, and subcutaneous route. The modern human vaccines are mostly composed of inactivated virus strains.

Technavio’s analysts forecast the global Human Combination Vaccines market to grow at a CAGR of 8.56% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global Human Combination Vaccines market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic versions of human combination vaccines.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Human Combination Vaccines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Merck
• Sanofi

[Other prominent vendors]
• Daiichi Sankyo
• Serum Institute of India
• Takeda Pharmaceuticals

[Market driver]
• Rise in cases of infectious diseases
• For a full, detailed list, view our report

[Market challenge]
• Requirement of cold chain logistics
• For a full, detailed list, view our report

[Market trend]
• Government-sponsored programs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Human combination vaccines: An overview
• Need for development of combination vaccines
• Technical challenges faced during formulation of combination vaccines
• Strategies for developing human combination vaccines

PART 06: Key clinical trials

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by vaccine type
• Human combination inactivated vaccines
• Human combination live attenuated vaccines

PART 09: Geographical segmentation
• Human combination vaccines market in Americas
• Human combination vaccines market in EMEA
• Human combination vaccines market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Government-sponsored programs
• Growing interest toward R&D of newer vaccines
• More focus on emerging countries
• Public–private initiatives
• Threat of bioterrorism
• Improvements in healthcare infrastructure

PART 13: Vendor landscape
• Competitive landscape

PART 14: Key vendor analysis
• GlaxoSmithKline
• Merck
• Sanofi
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Advantages of human combination vaccines
Exhibit 02: Marketed human combination vaccines: Overview
Exhibit 03: Pipeline molecule based on vendors
Exhibit 04: Product pipeline
Exhibit 05: Pipeline analysis of key clinical trials
Exhibit 06: Global human combination vaccines market: Snapshot
Exhibit 07: Global human combination vaccines market 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis in global human combination vaccines market
Exhibit 09: Five forces analysis
Exhibit 10: Human combination vaccines market by vaccine type
Exhibit 11: Global human combination vaccine market share by vaccine type 2016
Exhibit 12: Human combination inactivated vaccines market 2016-2021 ($ millions)
Exhibit 13: Human combination live attenuated vaccines market 2016-2021 ($ millions)
Exhibit 14: Global human combination vaccines market by geography 2016 and 2021
Exhibit 15: Global human combination vaccines market revenue by geography 2016-2021 ($ millions)
Exhibit 16: Global human combination vaccines market share by geography 2016-2021
Exhibit 17: Market scenario in Americas
Exhibit 18: Human combination vaccines market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: Human combination vaccines market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: Human combination vaccines market in APAC 2016-2021 ($ millions)
Exhibit 23: Total number of children aged 0-5 years in US (millions)
Exhibit 24: Trends in population growth in developing regions
Exhibit 25: Competitive structure analysis of global human combination vaccines market 2016
Exhibit 26: GlaxoSmithKline: Key highlights
Exhibit 27: GlaxoSmithKline: Strength assessment
Exhibit 28: GlaxoSmithKline: Strategy assessment
Exhibit 29: GlaxoSmithKline: Opportunity assessment
Exhibit 30: Merck: Key highlights
Exhibit 31: Merck: Strength assessment
Exhibit 32: Merck: Strategy assessment
Exhibit 33: Merck: Opportunity assessment
Exhibit 34: Sanofi: Key highlights
Exhibit 35: Sanofi: Strength assessment
Exhibit 36: Sanofi: Strategy assessment
Exhibit 37: Sanofi: Opportunity assessment



【掲載企業】

GlaxoSmithKline, Merck, Sanofi, Daiichi Sankyo, Serum Institute of India, and Takeda Pharmaceuticals.

【資料のキーワード】

ヒト混合ワクチン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[ヒト混合ワクチンの世界市場2017-2021] (Global Human Combination Vaccines Market 2017-2021 / IRTNTR12763)販売に関する免責事項
[ヒト混合ワクチンの世界市場2017-2021] (Global Human Combination Vaccines Market 2017-2021 / IRTNTR12763)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆